Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis

Published:

20241021 -

PLoS One

Author(s):

Denise Evans, Kamban Hirasen, Clive Ramushu, Lawrence Long, Edina Sinanovic, Francesca Conradie, Pauline Howell, Xavier Padanilam, Hannetjie Ferreira, Ebrahim Variaiva, Shakira Rajaram, Aastha Gupta, Sandeep Juneja, Norbert Ndjeka

Tags:

Bedaquiline (TMC-207), BPaL, Linezolid, MDR-TB, Pretomanid/PA-824, TB Drug Market, TB Market